fda glp-1 warning november 2025 Receptor Agonists and vision risk Despite FDA's crackdown, pharma is

Increasing attention has been directed toward the concept of a therapeutic window of opportunity, which frames early PsA as a transitional phase characterized by musculoskeletal symptoms such as arthralgia, dactylitis, and subclinical enthesitis in patients with PsO, often preceding clinically evident arthritis ( These considerations highlight the need for future studies specifically designed to evaluate GLP-1RAs in patients at high risk of PsA, particularly those with subclinical inflammation or early musculoskeletal symptoms

Youre dehydrated: Delayed gastric emptying means you feel satisfied with less food, which can lead to reduced eating and drinking

Doctors use lab tests to check your Vitamin B12 levels

Infants have distinct metabolic capacities than adults